Lasa Supergenerics Ltd. · NSE:LASA

Lasa Supergenerics — FY2020 Earnings Presentation

21 slides from Lasa Supergenerics's earnings presentation, Jun 19, 2020

  1. Slide 1: Q4 & FY20 Investor Presentation

    Q4 Q3&&FY20 9MFY20 Investor Investor Presentation Presentation 1

  2. Slide 2: WE CARE

    Q3FY20 Financial Highlights (Standalone) WE CARE 2

  3. Slide 3: About Lasa Supergenerics Limited

    Q3FY20 About LASA SUPERGENERICS Financial Highlights (Standalone) LIMITED Lasa Supergenerics Limited (‘Lasa’) is a vertically integrated group spanning the entire animal and human healthcare value chain—from discovery-to-delivery, with established credentials in research, manufacturing and global ma

  4. Slide 4: Products

    Products Q3FY20 Financial Highlights (Standalone) API PRODUCTS ANIMAL FEED INGREDIANTS OTHER API PRODUCTS REAGENTS FOR THERAPEUTIC USE 4

  5. Slide 5: Key Managerial Personnel

    Key Managerial Key Managerial Personnel Personnel Dr. Omkar P. Herlekar - Chairman and Managing Director Upon assuming the leadership of Lasa, Dr. Herlekar charted a multi-pronged approach for its corporate growth. Envisioning a global presence for the group, he played a pivotal role in establishing

  6. Slide 6: Financials

    FINANCIALS 6

  7. Slide 7: Snapshot – Q4 FY20 (Standalone)

    Q3FY20 Financial Highlights (Standalone) Snapshot – Q4 FY20 (Standalone) Total Revenue – Rs. 485.85 Mn EBITDA - Rs. 90.30 Mn Profit Before Tax - Rs. 24.4Mn Profit After Tax - Rs. 25.80 Mn EPS - Rs. 0.89 7

  8. Slide 8: Snapshot – FY20 (Standalone)

    Q3FY20 Financial Highlights (Standalone) Snapshot – FY20 (Standalone) Operating Revenue – Rs. 1672.7 Mn EBITDA - Rs. 299.5 Mn Profit Before Tax - Rs. 47.4 Mn Profit After Tax - Rs. 36.30Mn EPS - Rs. 1.26 8

  9. Slide 9: Performance Indicators – Q4 FY20 (Standalone)

    Performance Indicators – Q4 FY20 (Standalone) Operating Revenue (Rs. Mn) EBITDA (Rs. Mn) 92 600 90.3 90 500 485.5 88 392.9 400 86 84 300 82 81.64 200 80 100 78 76 0 Q3FY20 Q4FY20 Q3FY20 Q4FY20 Profit Before Tax (Rs. Mn) Profit After Tax (Rs. Mn) 25.805 24.6 25.8 25.8 24.4 24.4 25.795 24.2 25.79 24 2

  10. Slide 10: Performance Indicators – FY20 (Standalone)

    Performance Indicators – FY20 (Standalone) Operating Revenue (Rs. Mn) EBITDA (Rs. Mn) 350 170 169.57 299.5 169.5 300 169 250 168.5 200 168 150 111.1 167.5 167.27 100 167 50 166.5 0 166 FY19 FY20 FY19 FY20 Profit Before Tax (Rs. Mn) Profit After Tax (Rs. Mn) 60 100 36.3 40 47.4 20 50 0 0 FY19 FY20 -2

  11. Slide 11: Q4 FY20 Income Statement (IND-AS) (Standalone)

    Q4 FY20 INCOME STATEMENT (IND-AS) (Standalone) INCOME STATEMENT (INR Mn) Q4-FY20 Q3-FY20 Q-o-Q Q4-FY19 Y-o-Y Total Revenue 486.47 393.15 23.7% 423.81 12.4% Total Expenses 462.16 369.68 16.5% 454.10 1.8% EBITDA 90.3 83.8 7.8% 30.7 194.1 EBITDA Margins (%) 18.59% 21.33% 7.31% Depreciation 43.60 43.9 -

  12. Slide 12: FY20 Income Statement (IND-AS) (Standalone)

    FY20 INCOME STATEMENT (IND-AS) (Standalone) INCOME STATEMENT (INR Mn) FY20 FY19 Y-o-Y Total Revenue 1675.02 1700.4 -1.5% Total Expenses 1627.66 1861.50 (12.6)% EBITDA 299.5 111.1 169.6% EBITDA Margins (%) 17.91% 6.55% Depreciation 173.4 193.08 (10.2)% EBIT 128.4 -77.3 266.1 EBIT Margins (%) 7.68 -4.

  13. Slide 13: Balance Sheet FY 19-20

    BALANCE SHEET FY 19-20 PARTICULARS (INR Mn) FY20 FY19 PARTICULARS (INR Mn) FY20 FY19 EQUITIES & LIABILITIES ASSETS (A) Equity 1. Non Current Assets 1. Equity Share Capital 406.73 228.64 (A) Property, Plant and Equipment's 1459.56 1556.63 2. Other Equity 1,007.93 824.33 (B) Capital Work-in-progress -

  14. Slide 14: Gallery

    GALLERY 14

  15. Slide 15: Plant Units Gallery

    Rencal – Unit 3 Mahad – Unit 1 Urdhwa – Unit 2 15

  16. Slide 16: Certifications

    CERTIFICATIONS 16

  17. Slide 17: Certifications and Licenses

    ISO 9001:2015 Certificate Albendazole License – FDA (M.S) Good Manufacturing Certificate – PESO License FDA (M.S) 17

  18. Slide 18: Corporate Social Responsibility

    CORPORATE SOCIAL RESPONSIBILITY 18

  19. Slide 19: 19

    19

  20. Slide 20: Disclaimer

    Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d

  21. Slide 21: Contact details

    Mr. Hitesh Wadhwani Mr. Gaurav Girdhar Lasa Supergenerics Ltd Concept Investor Relations Tel: 7798888147 Tel: +022 40558934 / 7798232425 E-mail: hitesh@lasalabs.com E-mail: gaurav.g@conceptprcom 21

Lasa Supergenerics — FY2020 Earnings Presentation on 6ix